Orasis CEO, Elad Kedar, Interviewed by Endpoints News about Recent Series C Round
Elad Kedar discuss the Presbyopia Market and the closing of the recent Series C round with Endpoints News.
Orasis Closes $30MM Series C Round for Phase III Trials and Pre-Commercialization Activities.
Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the treatment of presbyopia symptoms, today announced the closing of a $30 million Series C financing. The financing was co-led by new investor Bluestem Capital and returning investor Visionary Ventures, with participation from other returning investors Sequoia Capital, SBI (Japan) Innovation Fund, Maverick Ventures, LifeSci Venture Partners and additional investors.
TearClear Raises $22 Million & Adds Stuart Raetzman to BOD to Advance Multiple Clinical Programs in Development
TearClear Raises $22 Million from Visionary Ventures, Bluestem Capital, Flying L Partners, and KKR to Advance Multiple Clinical Programs in Development. In addition to the financing, TearClear also announces the appointment of the former Chief Executive Officer of Galderma, Stuart Raetzman, to Board of Directors.
Re-Vana in Northern Ireland’s Top 10 Most Innovative Technology Companies
Re-Vana ranks 10th in BusinessCloud’s Northern Ireland Tech 50 ranking for 2020.
Visionary Partner & KOL, Ehsan Sadri, Weighs in on Tarsus Pharmaceuticals in CRST Article
Tarsus TP-03: Potential Game-Changer for Demodex Blepharitis
Tarsus Pharmaceuticals Announces Appointment of New COO and CFO
Sesha Neervannan, PhD, to assume position of Chief Operating Officer; Leo Greenstein to assume position of Chief Financial Officer
Optometric Management Interviews TearClear CEO Robert Dempsey
Robert J. Dempsey recently joined TearClear, an emerging global ophthalmic pharmaceutical company with a focus on eye drops that are preserved safely prior to administering dosing, as Chief Executive Officer. Prior to this role, Mr. Dempsey held positions at Shire (Takeda, now Novartis), Bausch + Lomb, Allergan and Inspire Pharmaceuticals. What follows is a Q&A with Mr. Dempsey, where he reveals, among other things, his love of American history.
Re-Vana Therapeutics
Re-Vana Therapeutics is developing sustained release ophthalmic therapeutics that can reduce the frequency of intravitreal injections required to treat a wide range of retinal diseases, including neovascular age-related macular degeneration. The Re-Vana platform has the potential to deliver at least 4 to 6 months sustained delivery of a large molecule biologic, including anti-VEGF therapies. Re-Vana’s technology could spur a new generation of glaucoma medications that may reduce or eliminate the need for eye drops by delivering small molecules for 6 to 9 months or longer.
Re-Vana Therapeutics Completes of $3.25MM Pre-Series A Financing
Re-Vana Completes $3.25MM Pre-Series A Financing led by Visionary Ventures and ExSight Ventures to Support Pre-clinical Development of Sustained Release Biologic and Small Molecule Therapeutics.
Tarsus Presents Positive Phase IIb Results of TP-03
Tarsus Presents Positive Results of the Jupiter Study, a Phase 2b Randomized Controlled Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Blepharitis Due to Demodex Infestation, at AOA 2020 Virtual Meeting